Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

Fig. 1

Kaplan-Meier analysis of Menacalc in the ANN patient cohort (n = 403, top left), in a subset of patients who received chemotherapy and/or hormone therapy (n = 261, top right) and in a subset of the patient population that did not receive chemotherapy or hormone therapy (n = 142, bottom left). Menacalc scores were categorized as Menacalc high if they were at or above the median and Menacalc low if they were below the median. In brackets is the total number of patients followed by the number of patient deaths for each group

Back to article page